A Look Down Track B

A characteristic Scott psychiatry-explainer-plus-critique. He walks through the synaptogenesis/BDNF/TrkB pathway theory of antidepressant action, then engages a striking new Helsinki paper claiming antidepressants bind TrkB DIRECTLY (so 'the serotonin doesn't matter at all'). Rather than credulously amplify a would-be decade-defining breakthrough, he mounts a disciplined psychiatrist's rebuttal: if effects are non-monoaminergic, why are so many monoaminergic substances antidepressants (5-HTP, MAOIs proportional to MAOI strength, serotonin-depletion causing depression)? He flags the paper's cherry-picked 2-vs-1 mouse-knockout citation, the questionable 'antidepressants accumulate over months' claim (only fluoxetine does; the other cite is a 1995 lysosome speculation), and the mice-work-great-but-humans-barely-respond tension — then defers appropriately to biochemists on Derek Lowe's Twitter noting TrkB assays are notoriously false-positive-prone. Ends with well-calibrated predictions and epistemic humility.

Quality 70 · Strong. Strong (70). A rigorous, well-argued, replication-aware takedown that models how to weigh one exciting new study against a large existing literature; genuinely useful and memorable but narrow/technical, not field-defining — sits with the other strong Scott psychopharm pieces (Antidepressant-effect-sizes 70, Know-Your-Amphetamines 70).

Claude’s paradigm shift 46 · Moderate. Moderate (46). The skeptical synthesis is sharp but applies Scott's standing meta-science priors to a topical paper rather than installing a new frame.

Real-world impact 1 · Negligible. 1 — a blog analysis of a mechanistic dispute; no concrete real-world change.